Loading clinical trials...
Loading clinical trials...
Open-label Study Evaluating the Effect of Tusamitamab Ravtansine on the QTc Interval in Participants With Metastatic Solid Tumors
Conditions
Interventions
Tusamitamab ravtansine
Locations
7
United States
Mary Crowley Cancer Research Center Site Number : 8400002
Dallas, Texas, United States
Investigational Site Number : 0560001
Edegem, Belgium
Investigational Site Number : 2500001
Dijon, France
Investigational Site Number : 2500002
Marseille, France
Investigational Site Number : 7240002
Barcelona, Catalunya [Cataluña], Spain
Investigational Site Number : 7240001
Madrid, Madrid, Comunidad de, Spain
Start Date
October 3, 2022
Primary Completion Date
August 1, 2023
Completion Date
April 10, 2024
Last Updated
April 6, 2025
NCT04550494
NCT05053971
NCT07209111
NCT07159659
NCT05039801
NCT07169851
Lead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions